Skip to content
⚠ KILLER HEALTH · THE HOLDING COMPANY · NOT MEDICAL ADVICE ⚠   ⚠ KILLER HEALTH · THE HOLDING COMPANY · NOT MEDICAL ADVICE ⚠   ⚠ KILLER HEALTH · THE HOLDING COMPANY · NOT MEDICAL ADVICE ⚠   ⚠ KILLER HEALTH · THE HOLDING COMPANY · NOT MEDICAL ADVICE ⚠   
KKILLER*.HEALTH

/ Kills / RECOVERY KILL

#01 / SLOW HEALINGEducation · not medical advice

RECOVERY KILL

“Recover like you borrowed the body.”

Foundations firstThe evidenceLabs to discussQuestions for your clinician

// 01

The goal.

Get injured tissue — tendon, ligament, muscle, gut lining, skin — back to work, and get you back to training without re-injury.

Tendons and ligaments heal slowly because they have a poor blood supply. Most of what speeds recovery is boring, well-studied and free. The peptides people talk about here are, for now, mostly an animal-study story.

// 02

Foundations first.

01

Graded loading

Progressive, supervised rehab is the best-evidenced treatment for tendon problems. Total rest usually makes tendons weaker, not stronger. A good physical therapist is the highest-yield spend in this category.

02

Sleep

Tissue repair and growth-hormone release happen overnight. Short sleep is linked to higher injury rates in athletes.

03

Protein and total energy

Under-eating slows healing. Adequate protein across the day supports the rebuilding of muscle and connective tissue.

04

Don’t smoke

Smoking reliably slows tendon, bone and wound healing. Stopping is one of the few interventions with strong human evidence.

05

A real diagnosis

If something is not improving after a few weeks of sensible rehab, get it examined and imaged. A partial tear and tendinopathy are different problems.

The free version of all of this: S.T.A.R.T.E.D.

// 03

The compounds people ask about.

These are the compounds that come up most in recovery conversations, on the podcast and in the book. Here is what they are and what the research does and does not show.

No doses, schedules, combinations or sources — by design.

Evidence · Mostly animal and lab studies

BPC-157

“Body protection compound”

What it is

A synthetic chain of 15 amino acids, modelled on a fragment of a protein found in human gastric juice. Most of the published research comes from one university group in Zagreb.

How it’s thought to work

In animal and cell studies it appears to encourage new blood-vessel growth into damaged tissue, influence nitric-oxide signalling, raise growth-hormone receptor levels on tendon cells and damp down inflammation. None of that has been confirmed in people.

What the research shows

  • —Animal studies: a large body of rat and rabbit work on tendon, ligament, muscle and gut injury, mostly from the same research group, with a consistent faster-healing signal. Independent replication is limited.
  • —Human studies: a handful of small, uncontrolled reports. There is no completed large randomized controlled trial for any musculoskeletal use.
  • —Bottom line: an interesting animal signal and very little human evidence. Anyone who tells you it is proven in people is ahead of the data.

Risks and side effects

  • —Long-term safety in humans is unknown. FDA cites possible immune reactions (immunogenicity), peptide impurities and too little safety information to know whether it causes harm.
  • —Because it promotes blood-vessel growth in animal studies, a history of cancer is a serious reason for caution — raise it with an oncologist or your clinician.
  • —No data in pregnancy or breastfeeding.
  • —Products sold online are unregulated; what is in the vial may not match the label.

Regulatory status

  • —Not approved by FDA for any use, and not approved as a medicine in the US.
  • —FDA put it in “category 2” of its compounding policy — substances that may present significant safety risks. The nomination was later withdrawn, and in April 2026 FDA moved it to the “nominated but withdrawn” list on the same page, which still sets out its safety concerns. Withdrawal does not make it approved, and it does not place it in category 1 (the substances FDA is still evaluating for compounding).
  • —In July 2026 FDA’s Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding BPC-157 to the list of substances pharmacies may compound. FDA staff had recommended against it. The vote is not binding; as of 2 October 2026 FDA has not added it.
  • —Prohibited in sport by the World Anti-Doping Agency.

Sources

Evidence · Animal and lab studies only

TB-500

Thymosin beta-4 fragment (LKKTETQ)

What it is

A synthetic seven-amino-acid fragment of thymosin beta-4, a 43-amino-acid protein found in most human cells. TB-500 is not the same molecule as thymosin beta-4, even though the names are often used as if it were.

How it’s thought to work

Thymosin beta-4 binds actin, the scaffolding protein cells use to move. In lab and animal studies the full protein affects cell migration, blood-vessel growth and inflammation. How much of that the short fragment reproduces is less clear.

What the research shows

  • —Animal and lab studies of full-length thymosin beta-4 in wound, heart and eye models.
  • —Human trials have tested the full-length protein (for example as eye drops and topical wound products), not the TB-500 fragment.
  • —FDA states it has not identified any human exposure data for the fragment.

Risks and side effects

  • —Safety in humans is unknown. FDA cites possible immune reactions and peptide impurities.
  • —Like other compounds that promote blood-vessel growth in animal studies, a history of cancer is a reason for serious caution.
  • —No data in pregnancy or breastfeeding.

Regulatory status

  • —Not approved by FDA for any use.
  • —FDA put it in “category 2” of its compounding policy — substances that may present significant safety risks. The nomination was later withdrawn, and in April 2026 FDA moved it to the “nominated but withdrawn” list on the same page, which still sets out its safety concerns. Withdrawal does not make it approved, and it does not place it in category 1 (the substances FDA is still evaluating for compounding).
  • —It was one of the peptides reviewed at FDA’s Pharmacy Compounding Advisory Committee in July 2026. The committee’s votes are recommendations only; as of 2 October 2026 FDA has not added it to the list of substances pharmacies may compound.
  • —Thymosin beta-4 and its derivatives are prohibited in sport by the World Anti-Doping Agency.

Sources

Evidence · Small human studies

GHK-Cu

Copper tripeptide-1

What it is

A three-amino-acid peptide (glycine–histidine–lysine) bound to copper. It occurs naturally in human plasma and is a common ingredient in skin-care products.

How it’s thought to work

In lab studies it influences collagen and other structural proteins in skin and connective tissue, and the remodelling phase of wound repair.

What the research shows

  • —Topical use: small cosmetic studies on skin appearance, many of them industry-funded.
  • —Wound repair: mostly animal and lab work.
  • —Other routes: very little human data.

Risks and side effects

  • —Skin irritation with topical products; avoid with a known copper sensitivity.
  • —For non-topical use FDA cites possible immune reactions and limited human safety data.

Regulatory status

  • —Not approved by FDA as a drug. It is sold legally as a cosmetic ingredient, which FDA does not review for effectiveness.
  • —For compounding, FDA placed GHK-Cu for injectable routes in category 2 (may present significant safety risks); that nomination was withdrawn in April 2026 and it now sits on FDA’s “nominated but withdrawn” list.
  • —GHK-Cu for non-injectable routes is in category 1 (still under FDA evaluation) as of 14 May 2026. FDA says it will consult its advisory committee about it before the end of February 2027.

Sources

// 04

Labs to discuss.

Worth asking your clinician about before you change anything:

  • —CBC — anemia slows recovery and limits training.
  • —Ferritin and iron studies.
  • —25-OH vitamin D.
  • —HbA1c — high blood sugar impairs healing.
  • —hs-CRP — a general marker of inflammation.
  • —Imaging (ultrasound or MRI) when an injury is not improving.
The full baseline panel →

// 05

Questions for your clinician.

  1. 01What exactly is injured, and how sure are we?
  2. 02What rehab plan has the best evidence for this injury, and how will we measure progress?
  3. 03Is there anything in my history — including cancer — that makes experimental compounds a bad idea for me?
  4. 04If I am considering an unapproved compound, what are the known risks, and what would make you tell me to stop?

// 06

Keep reading.

Proactive Health

The Labs To Run Before Your First Peptide

Peptides Demystified

BPC-157 vs TB-500: What The Evidence Actually Shows

// 07

Related kills.

#02 / INSOMNIA

SLEEP KILL

“Die better at night.”

DSIPEpitalonPinealon
FOUNDATIONS · EVIDENCE · LABSREAD →
#03 / ADIPOSE

FAT KILL

“Not a diet. A vendetta.”

TirzepatideRetatrutideAOD-9604
FOUNDATIONS · EVIDENCE · LABSREAD →
#04 / TIME

LONGEVITY KILL

“Outlive your enemies.”

EpitalonThymalinNAD+
FOUNDATIONS · EVIDENCE · LABSREAD →

// Education · not medical advice

Talk to a licensed clinician.

This is education, not medical advice. KILLER*.HEALTH does not publish doses, schedules or combinations, does not sell or recommend any compound, and does not tell you where to get one. Compounds described here that are not FDA-approved have not been shown to be safe or effective. Before starting, stopping or changing anything about your health, talk to a licensed clinician who knows your history.